Join Endpoints and the Cancer Research Institute for a panel discussion with oncology newsmakers
Where is the cancer R&D revolution headed?
Over the past 5 years oncology research has exploded, with fast-paced development schedules delivering breakthrough drugs that are changing the standard of care. But along the way, a bubble has developed, with companies pursuing hundreds of new studies and grabbing pipeline assets in the rush to multiply checkpoint drugs and compete with therapies already on the market. Endpoints News Editor John Carroll will review some startling new data on the cancer pipeline and lead a discussion on how this revolution can best be managed — to the advantage of patients, physicians and the biopharma companies leading the boom. This is one event you won’t want to miss.
- When: Tuesday, 9 Jan 2018 7:00—8:45am PT
- Where: Hilton San Francisco Union Square Hotel
- Format: Seated Breakfast and Panel Discussion
Need help? Get help or email: firstname.lastname@example.org
Founder, Friends of Cancer Research
President, Novartis Institutes for BioMedical Research
SVP, Immuno-oncology at AstraZeneca
CMO, Cancer Research Institute
Deputy Director (acting), Office of Hematology Oncology Products at FDA